Nervous Disorder TRIZ Cases

CAR-T cells targeting B-cell maturation antigens reduce CSF cytokines, chemokines, and complement linked to CNS inflammation.

Prenylated quinoline compounds balance PPAR activity to improve lipid metabolism while limiting adverse effects linked to potent agonism.

Engineered red blood cells express GAMT and MAT to convert toxic GAA into creatine, reducing reliance on strict supplementation.

Antibodies, aptamers, or nucleic acid probes make COTL1 measurable for precise cognitive dysfunction diagnosis.

Partial hydrogel removal preserves handling protection while helping 3D post-mitotic neuronal tissue integrate after implantation.

SARM1-inhibiting compounds aim to preserve NAD+ levels, stabilize axons, and reduce degeneration in neurodegenerative conditions.

Conventional levodopa can lose efficacy and cause adverse reactions; PFC-37 protects MPP+-injured PC12 cells as a neuroprotective drug candidate.

Four herbal extracts are combined at defined ratios to address anxiety while avoiding addiction and adverse reactions linked to Western medications.

See how cannabidiol addresses treatment-resistant seizures linked to KCN mutations and can reduce seizure frequency in rare epilepsy syndromes.

Selective alpha4-beta-delta GABA-A antagonism blocks harmful steroid effects linked to Tourette’s, OCD, and gambling disorder.

STRO-1+ cell populations address the gap between stroke neuroprotection and restoration by supporting neuron survival, regeneration, and cerebral function.

Immediate and modified release components balance rapid onset and sustained gamma-hydroxybutyrate levels for narcolepsy treatment.

Flavones such as quercetin act as adenosine receptor antagonists to support alertness and energy with less jitteriness than caffeine.

Changing carbon-chain saturation and functional groups creates fatty acid analogs for chronic pain relief without opioid addiction.

Formula (I) compounds activate Nrf2 through non-covalent binding, reducing interaction with non-target proteins linked to heart failure risk.

Layered cellulose and polymethacrylate coatings help modified-release drugs resist alcohol-triggered dose dumping while preserving controlled release.

Stem cells pre-enriched with healthy mitochondria address limited CNS treatments by enhancing mitochondrial activity in one treatment round.

Topical P-gp and MRP1 inducers pretreat sensory neurons and hair follicles, reducing chemotherapy accumulation linked to CIPN and alopecia.

Guide RNA-directed Cas9 or Cpf1 breaks target SCN9A to improve editing precision and enable lasting treatment of pain-related disorders.

Novel compounds modulate serotonin and dopamine signaling to address poor OCD response rates and reduce addiction risk linked to strong opioid agents.

An Iba1 promoter with miR-9 and miR-129 targets improves specific exogenous gene expression in microglia.

Neprilysin-overexpressing stem cells, conditioned medium, and exosomes limit amyloid beta, protect nerve cells, and improve cognition.

Umbilical cord subepithelial cells use defined markers and culture expansion to support allogenic regenerative therapy.

Cyclodextrin complexation protects unstable sulforaphene, improving its bioavailability while preserving activity for mitochondrial disorder treatment.

Amniotic fluid or its extract supports cell amplification in culture while supporting tissue repair and addressing mutation, differentiation, and contamination risks.

New roluperidone solid forms and salts address limited processing, stability, solubility, and bioavailability in pharmaceutical formulations.

RAP-103 blocks chemokine ligand binding and receptor desensitization, helping lower morphine doses while preserving analgesic efficacy.

CD33-binding antibodies target CD33-expressing cancer cells to improve cytotoxicity and support diagnostic imaging for AML.

Existing orexin-2 agonists can have inadequate activity, CNS permeability, pharmacokinetics, or safety; this case varies piperidino structure to address those limits.

Defined terpene blends address generic cannabinoid products by tailoring compositions for sleep, pain, and neuroprotection.

Intra-cisterna magna administration of an AAVhu68 rAAV delivers functional human ARSA to the CNS, aiming to restore enzyme activity in early-onset MLD.

Water-soluble aerosol droplets are sized for nasal receptor deposition, improving delivery while limiting lung penetration.

Periodic dosing limits chronic high-dose exposure while maintaining rapid antidepressant efficacy and reducing mutagenicity risk in MDD.

Selective GSK3α and GSK3β compounds target kinase isoforms to provide effective inhibition while minimizing off-target effects.

Allyl- and propargylamine substitutions create phenethylamine and tryptamine compounds aimed at therapeutic effects with fewer adverse reactions.

Targeting peptides inserted into AAV1 capsids improve brain endothelial-cell specificity for therapeutic delivery across the blood-brain barrier.

The CNS delivery challenge is addressed with intrathecal rAAV9 carrying MECP2 to the brain and spinal cord.

Conventional lactic acid bacteria may not boost IL-12p70 and IFN-λ effectively; MG-LAB279 supports antiviral immunity while limiting inflammation.

Guide RNAs direct CRISPR/Cas9 to excise the C9ORF72 repeat expansion, reducing pathogenic dipeptide repeats and TDP-43 pathology.

Sex-specific NAP peptide dosing addresses bell-shaped responses, improving PSP treatment efficacy while avoiding adverse effects.

PRG-A-01 and PRG-A-04 inhibit WT-SOD1 aggregation and misfolding, blocking protein propagation and reducing neuronal cell death in ALS models.

CNCM-deposited Lachnospiraceae and Ruminococcus strains are formulated for oral use to address aging- and Alzheimer’s-related memory decline.

Combining NMN with resveratrol, ergothioneine, and hydroxytyrosol targets severe oxidant stress beyond NMN alone.

Intranasal hrVCP inhibits complement activation to reduce neuroinflammation and protect cognition in APOE ε4 carriers.

Chronic nerve injury can cause central sensitization; humanized scFv antibodies inhibit CCK-BR to relieve neuropathic pain without opioids.

Dual-target compounds inhibit ALDH2 and OATP1-mediated uptake to address limited alcohol use disorder treatments.

A staged Wnt activator increase with dual SMAD inhibition and SHH signaling reduces immature markers in stem-cell-derived mDA neurons.

Targeting reduced TPK activity, this case uses TPK agonists to increase TDP and support cerebral glucose metabolism in Alzheimer’s disease.

Conventional antidepressants can cause side effects; this case uses B. longum NCC3001 to modulate gut-brain signaling for depressive symptoms.

Limited Alzheimer’s treatments mainly relieve symptoms; combining acyclovir with dexamethasone targets HSV-1 and neuroinflammation.